Search

Your search keyword '"Tobias Engel Ayer Botrel"' showing total 2 results
Start Over Author "Tobias Engel Ayer Botrel" Journal plos one
2 results on '"Tobias Engel Ayer Botrel"'

1. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Author

Tobias Engel Ayer Botrel, Otávio Clark, Antônio Carlos Lima Pompeo, Francisco Flávio Horta Bretas, Marcus Vinicius Sadi, Ubirajara Ferreira, and Rodolfo Borges Dos Reis

Subjects
Medicine, Science
Abstract

Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC).Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI).The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p

Published
2016
Full Text
View/download PDF

2. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis

Author

Otavio Clark, Antonio Carlos Lima Pompeo, Rodolfo Borges dos Reis, Francisco Flávio Horta Bretas, Ubirajara Ferreira, Marcus Vinicius Sadi, and Tobias Engel Ayer Botrel

Subjects
Oncology, Male, Cancer Treatment, lcsh:Medicine, QUALIDADE DE VIDA, Docetaxel, Biochemistry, Androgen deprivation therapy, Prostate cancer, Database and Informatics Methods, White Blood Cells, 0302 clinical medicine, Mathematical and Statistical Techniques, Animal Cells, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine and Health Sciences, Medicine, 030212 general & internal medicine, Database Searching, lcsh:Science, Randomized Controlled Trials as Topic, Multidisciplinary, Pharmaceutics, Prostate Cancer, Hazard ratio, Prostate Diseases, Middle Aged, Tubulin Modulators, Treatment Outcome, Research Design, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Physical Sciences, Androgens, Taxoids, Patient Safety, Cellular Types, Statistics (Mathematics), medicine.drug, Research Article, medicine.medical_specialty, Neutropenia, Combination therapy, Clinical Research Design, Urology, Immune Cells, Immunology, Antineoplastic Agents, Research and Analysis Methods, 03 medical and health sciences, Drug Therapy, Internal medicine, Humans, Statistical Methods, Survival analysis, Aged, Blood Cells, business.industry, lcsh:R, Prostatic Neoplasms, Cancers and Neoplasms, Biology and Life Sciences, Androgen Antagonists, Cell Biology, medicine.disease, Survival Analysis, Hormones, Genitourinary Tract Tumors, lcsh:Q, Adverse Events, business, Febrile neutropenia, Mathematics, Receptor Antagonist Therapy, Meta-Analysis
Abstract

Objective Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC). Methods Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI). Results The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results